• Home
  • Search Results

Search Results

Young Adult (18-34)
Cancer
399 studies match your search
Coming Soon

Leukemia Treatment Study

In this study, we want to see how well a new drug called Quizartinib works for people with Leukemia who do not have a specific mutation called FLT3-ITD. We want to see if this new drug helps improve the condition.

Age & Gender
  • 18 years ~ 70 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
Coming Soon

MB-105 in Patients with CD5 Positive Relapsed/Refractory T-Cell Lymphoma

The purpose of this study is to find out how safe and effective a new CAR-T study treatment, called MB-105, is for people with T-cell lymphoma. MB-105 is an experimental study treatment. This means it is not approved for general use by the U.S. Food and Drug Administration (FDA) and, as such, can only be used in research studies.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Open

Petosemtamab Drug Study

Do you have incurable, metastatic/recurrent head and neck squamous cell carcinoma? If so, you may be able to take part in a study to see if a new drug called petosemtamab is effective. We want to see if petosemtamab works better than the treatments doctors usually use for head and neck squamous cell carcinoma. Compensation provided.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Head and Neck)
Open

Study of RP1 in Organ and Cell Transplant Patients With Skin Cancer

Have you had an organ transplant or hematopoietic cell transplant and have advanced cutaneous squamous cell carcinoma? If so, you might be eligible to take part in a study to see if an investigation drug, RP1, can help treat your skin cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Other Cancers)
Not currently enrolling

Radiation-Induced Xerostomia Long-Term Follow-Up Study

In this study, we want to asses the long-term safety of using a virus to deliver a gene, AAV2-hAQP1, and how effective this gene is at treating dry mouth in people who have received radiation therapy for head and neck cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Head and Neck)
Open

Study for Patients with Non-small Cell Lung Cancer

Have you been diagnosed with Stage III non-small cell lung cancer? Is your cancer advanced and not able to to removed? If so, you might be able to participate in a study that looks at a study drug to see if it can help the radiation treatment work better against your cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lung)
Not currently enrolling

Dose-escalation and expansion study of BAY 3375968 (anti-CCR8 antibody) as monotherapy and in combination with pembrolizumab in selected advanced solid tumors

This study will evaluate BAY 3375968 as a new immunotherapeutic agent in advanced solid tumor settings of high medical need.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Breast, Colorectal, and 5 more)

Dara-RVd Induction for newly diagnosed multiple myeloma with autologous stem cell transplantation

In this study, we want to see what happens when one of the drugs in a 4-drug combination called Dara-RVd is given once a week instead of twice a week. We will look at how this timing change affects the outcome of multiple myeloma with autologous stem cell transplantation. This is a hybrid decentralized study where some if not all assessments may be performed close to your home.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Multiple Myeloma)
Open

PRevention Of Frailty with Fisetin (PROFFi) in Breast Cancer Survivors

Are you a breast cancer survivor? if soy you may be eligible to participate in this research study that is looking at the effectiveness of fisetin and/or exercise on physical function assessed using a 6 minute walking distance in chemotherapy-treated postmenopausal breast cancer survivors

Age & Gender
  • 18 years ~ 70 years
  • Female, Gender Inclusive
Study Interest
  • Cancer (Breast)
Open

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors

Do you have With Locally Advanced or Metastatic Solid Tumors of the Head or Neck? If so, you may be able to participate in a research study to to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®).

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Head and Neck)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research